Alderley Park, Cheshire, U.K. – 8 September 2026 – Infex Therapeutics, a leading anti-infectives specialist, today announced new data from its Phase IIa study of RESP-X (INFEX702), a first-in-class anti-virulence monoclonal antibody, in non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa (Pa), which will be presented in a late-breaking poster abstract at the European Respiratory Society (ERS) Congress 2026 at 12:30-14:00 CEST in Barcelona, Spain.